New UK Cancer Drugs Fund Dismays Pharma, Charities
Executive Summary
The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation. Pharma companies believe they will have to shoulder additional financial risks while patients will still not get full access to the medicines they need.
You may also be interested in...
UK’s NICE Xalkori Recommendation Signals Issues For Securing Market Access For Rarer Cancer Drugs
Two more drugs are set to enter England’s Cancer Drugs Fund: Tesaro’s Zejula and Pfizer’s Xalkori. Recommendations on the latter highlight difficulties for rarer cancer treatments.
AbbVie's Humira Tops NHS Drug Spend List
A National Health Service spending report reveals the top 20 most expensive NICE approved drugs in England for 2016.
Roche Rejoins ABPI After Long Absence To Help Forum Address Brexit
Roche's decision to return to the UK industry body the ABPI reflects the Swiss company’s considerable commercial interests in Britain and the need for drug makers operating there to work more closely together as the Brexit process begins.